RNA-focused digital therapeutics firm Flamingo Therapeutics added a brand new member to its board of administrators, Dr. Ezra Cohen.
Flamingo produces RNA therapies for oncology and is backed by buyers comparable to Andera Companions, Bpifrance Giant Enterprise, Perceptive Advisors, Sphera and VIB.
Dr. Cohen has a historical past within the growth of prescription drugs, particularly head and neck cancers.
“The science and group at Flamingo are very spectacular, and I’m excited to affix the board following the current initiation of a number of vital oncology scientific research. I consider that Flamingo is uniquely positioned to enhance the top and neck remedy panorama with its RNA-targeting strategy, and I stay up for working with the group to ship new therapeutic choices for sufferers,” Dr. Cohen stated in a press release.
Life sciences software program firm Synthace introduced the appointment of Willem Baralt as its new chairman of the board. Baralt joined the corporate in February.
Synthace helps R&D scientists by automation throughout varied levels, together with experimental design, simulations and the creation of complete digital information.
Baralt has served on a number of boards of healthcare and charitable organizations. Most just lately, he served at transportable dialysis machine maker Quanta Dialysis Applied sciences, which secured $245 million in Collection D funding in 2021.
“I’m actually honored to affix the Synthace group at this time limit as it’s seeking to remodel the life sciences R&D panorama. With its digital experimentation platform, Synthace empowers scientists to design and execute experiments that had been beforehand unattainable. Synthace’s expertise is essential to enabling the R&D lab of the long run, permitting its clients to make new therapies whereas attaining radical time and value financial savings,” Mr. Baralt stated in a press release.
